A key program of VIOLIN is Vaxign, the first web - based publically available
vaccine target design tool based on bioinformatics analysis of genome sequences using the strategy of reverse vaccinology.
As a part of VIOLIN, we have developed Vaxign, the first web - based publically available
vaccine target design tool based on bioinformatics analysis of genome sequences using the strategy of reverse vaccinology.
Not exact matches
But researchers have had only a blurry picture of gp120's structure — not enough to
design well -
targeted drugs or mount an effective
vaccine strategy.
CTL119 manufacturing begins with a patient's own T cells, some of which are removed and then reprogrammed in Penn's Clinical Cell and
Vaccine Production Facility with a gene transfer technique
designed to teach the T cells to
target and kill tumor cells.
The finding could ultimately help improve flu
vaccine design: Because it takes time to manufacture
vaccines and inoculate the public, scientists must choose which strains to
target many months before the year's flu season begins.
Therefore, this could provide an important
target for disease interventions or
vaccine designs.
Identifying those two molecular
targets could help in the
design of better
vaccine strategies and tumor immunotherapies.»
The ability to
design new protein nanostructures could have useful implications in
targeted delivery of drugs, in
vaccine development and in plasmonics — manipulating electromagnetic signals to guide light diffraction for information technologies, energy production or other uses.
«This helps us understand that process, and it opens up the window to
targeting these cells by
designing vaccines that prevent autoimmunity.»
This is a very exciting discovery as it offers numerous possibilities of
designing therapies and
vaccines to
target these exposed surfaces to treat dengue as well as other related viruses such as Zika and chikungunya.
«This will allow us to
design better inhibitors or
vaccines that block invasion by
targeting multiple steps at the same time.»
These results may provide new ways for
vaccine researchers to
target HIV and may influence the
design of future HIV
vaccines.
More importantly, Gack found that avian, swine, and human flu viruses block TRIM25 to evade immune defense by RIG - I, unraveling a molecular
target for the
design of antiviral drugs and
vaccines.
The findings should help scientists to better understand the immune system, including autoimmune diseases, as well as provide potential new
targets for immunotherapy and
vaccine design.
My studies of cancer genomes have led to characterization of multiple pediatric and adult tumor types, to development of methods that identify and characterize changes in genomic heterogeneity, to defining acquired resistance mechanisms to
targeted therapies and to
designing novel, personalized
vaccines for individual patients.
«This loss - of - HLA mechanism suggests that, when
designing vaccines and cell - based therapies, we need to
target antigens that are presented to the immune system,» says Swanton.
«Seeing the
design of this key protein provides a
target for a potential
vaccine or even a therapeutic drug,» Smith said.
Physicians with the Personalized Medicine Program at The Tisch Cancer Institute have initiated a phase I proof - of - concept study, a fully personalized multipeptide therapeutic
vaccine designed to
target tumor - derived neoantigens for individual patients.
Animal Friends» Clinic Services Program consists of three core components each uniquely
designed to support a
targeted population by offering pets high - quality, low - cost spay / neuter,
vaccines and wellness services.
VANGUARD ® crLyme is a multivalent
vaccine which contains an OspA protein and a single OspC protein that is composed of antigenic material from seven common types of OspC found in Lyme - infected dogs in the U.S. 1 Its uniquely
targeted design helps provide a broad spectrum of coverage while delivering a low - reactive
vaccine by minimizing the amount of extraneous proteins administered to the dog.
About Vanguard crLyme Vanguard crLyme is a next - generation multivalent
vaccine which contains outer surface protein A (OspA) protein and a single OspC protein that is composed of antigenic material from seven common types of OspC found in Lyme - infected dogs in the U.S. 1 Its uniquely
targeted design helps provide a broad spectrum of coverage while delivering a low - reactive
vaccine by minimizing the amount of extraneous proteins administered to the dog.